Virtual Library
Start Your Search
H. Duan
Author of
-
+
P3.03 - Chemotherapy/Targeted Therapy (ID 719)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.03-004 - The Frequency and Clinical Implication of ALK, ROS1, RET and NTRK1 Gene Rearrangements in Adenosquamous Lung Carcinoma Patients (ID 8254)
09:30 - 09:30 | Author(s): H. Duan
- Abstract
Background:
Adenosquamous lung carcinoma (ASC) is a hybrid tumor made of adenocarcinoma and squamous cell carcinoma in one tumor. It is a rare disease with poorer prognosis comparing with the other common variants of non-small cell lung cancer (NSCLC). There is a persisting need for identifying more effective targeted therapy methods. Our previous study had examined the EGFR mutation status in lung ASC, the results showed that its mutation rate is similar with that of lung adenocarcinoma. Because the rarity of lung ASC, little is known about its gene rearrangement status and its relationship with the clinical characteristics.
Method:
ALK, ROS1, RET and NTRK1 gene rearrangement in lung ASC were examined by next generation sequencing methods, and further confirmed by fluorescent in situ hybridization (FISH) and/or immunohistochemistry methods. Tissue microarrays (TMAs) containing formalin fixed paraffin embedded (FFPE) lung ASC cases were used in this study.
Result:
This study included 53 cases of lung ASC totally. ALK/EML4 gene rearrangement was detected in 3 cases (5.7%), ROS1 fusion gene was detected in 1 cases (1.9%), RET gene rearrangement was detected in 1 case (1.9%). One of the ALK/EML4 rearrangement case had a concurrent EGFR exon 21 L858R mutation. All the rearrangement results can be further confirmed by FISH and/or immunohistochemistry methods. No association were identified between ALK/EML4 rearrangement and patient age, tumor size, clinical stage, positive pleural invasion, lymphovascular invasion, smoking status, lymph node metastasis, therapy methods, recurrence free survival (RFS) time or overall survival duration.
Conclusion:
The gene rearrangement rate of lung ASC is similar with that of lung adenocarcinoma, which further support our suggestion that lung ASC is a peculiar subtype of lung adenocarcinoma with a poorer prognosis than lung adenocarcinoma.
